Cautionary Tales with Tim Harford

Episode: "Stalling for Survival – A Lonely Fight Against a Deadly Medicine"

Release Date: September 5, 2025
Guest: Katie Hafner (Host of Lost Women of Science podcast)

Overview

This episode of “Cautionary Tales” explores how Dr. Frances Oldham Kelsey, a little-known Canadian-American pharmacologist and FDA reviewer, quietly resisted immense pressure to approve thalidomide for the U.S. market in 1960–61. Her relentless skepticism and insistence on scientific rigor averted a catastrophe, saving thousands of American babies from birth defects linked to the drug, which had already devastated families across Europe. Alongside host Tim Harford, guest Katie Hafner (of the "Lost Women in Science" podcast) unpacks the personal, scientific, and bureaucratic drama of Kelsey's lonely crusade—and discusses its wider legacy.

Key Discussion Points and Insights

1. Introducing Frances Oldham Kelsey and the Thalidomide Crisis

• Kelsey joined the U.S. FDA in 1960 as a medical reviewer; she was new, and pharmaceutical company William S. Merrell expected a routine approval for thalidomide (marketed as Kevidon) in time for Christmas.

• Thalidomide was already a bestselling sedative in 46 countries under names like Contergan (Germany) and Distaval (UK, Australia), with a supposed record of safety.

• Kelsey felt uneasy about the drug's clinical data, suspecting critical omissions and flaws ([03:09] Katie Hafner).

  “There was just a feeling that there was something in the data, or the absence of data, that was a cause of concern.”
  — Katie Hafner ([03:09])

2. Kelsey’s Background and Scientific Instincts

• Kelsey was unusually qualified: an MD, the first woman in the US with a PhD in pharmacology, and an early advocate of drug safety, informed by her experience investigating the Elixir Sulfanilamide poisoning in the 1930s ([07:07] Tim Harford).

• She had researched how drugs can cross the placental barrier, making her particularly attuned to risks for pregnant women ([09:29] Katie Hafner).

  “This experience she had with the quinine work was really important because... it planted a seed in her head about the placental barrier.”
  — Katie Hafner ([09:38])

3. Thalidomide’s Dodgy Application and Industry Pressure

• Merrell presented an avalanche of paperwork but relied on poorly translated German studies, weak evidence, and extraordinary safety claims (e.g., claiming no lethal dose) ([13:06] Katie Hafner).

• Labeling Kelsey the “new girl”, they expected her to rubber-stamp; instead, she persistently asked for more evidence and questioned the lack of animal studies.

  “She just didn't see the science, she didn't see the evidence... she just said, this just isn't working for me, guys.”
  — Katie Hafner ([12:13])

• Unable to reject the application outright without proof of harm, and facing an expiring 60-day review period, she innovatively declared the application “incomplete” to stall for time, infuriating Merrell ([14:05] Katie Hafner).

4. Chasing Evidence: Warnings from Abroad

• In January 1961, Kelsey read a British Medical Journal letter reporting nerve damage (peripheral neuritis) linked to thalidomide in UK patients—information omitted from Merrell’s application ([18:53] Katie Hafner).

• Merrell’s representative was evasive, and their clinical “evidence” consisted largely of anecdotal, sometimes ghostwritten doctor testimonials ([35:43] Katie Hafner).

  “There is this one doctor who was a golfing buddy... and [he] allegedly writes this paper in a journal declaring the drug very safe. And it was actually written by the Merrell people. Hello?”
  — Katie Hafner ([35:43])

5. The Human Cost: Tragedy Unfolds in Europe

• Birth defects (phocomelia, or severely shortened limbs) were being reported across continents, especially in West Germany. Pediatrician Widukind Lenz linked the devastation to thalidomide and publicly named the drug in late 1961 (story acknowledged by both Tim and Katie between [23:52] and [26:23]).
• The companies responded with hostility or denial, delaying action while damage mounted ([26:54] Katie Hafner).

6. The Near-Miss in America

• While Kelsey stalled FDA approval, Merrell distributed thalidomide samples to U.S. doctors through so-called clinical trials, often as a freebie for morning sickness, exposing thousands of women and resulting in some U.S. birth defects ([34:17] Katie Hafner).
• Merrell did not withdraw the application until March 1962, months after thalidomide’s withdrawal in Germany ([36:50] Katie Hafner).

7. Recognition, Reform, and Lasting Impact

• Kelsey’s vigilance became public in July 1962 via a Washington Post front-page story: "Heroine of FDA Keeps Bad Drug Off Market" ([37:24] Katie Hafner).
• She was honored with the nation's highest civilian award by President John F. Kennedy.
• Her actions prompted major FDA regulatory reform, ushering in modern, rigorous drug approval standards ([38:53] Katie Hafner).
• Thalidomide is now used, with extreme caution, for cancer and leprosy—an example of how drugs can have both disastrous and beneficial effects when properly studied ([40:11] Katie Hafner).

Notable Quotes & Memorable Moments

• On the broken FDA regulatory landscape pre-Kelsey:

  “It wasn't the FDA's job to make sure that the cough medicine wouldn't kill you. It was the FDA's job to make sure that the cough medicine had what the manufacturers said it had in it.”
  — Tim Harford ([08:23])

• On the power and peril of “gut feeling” in science:

  “She just knew it didn’t sit right with her. So, there’s a lot to be said for going with one’s gut, right?”
  — Katie Hafner ([29:41])

• On company conduct:

  “They did nothing ... Grunenthal was extremely hostile to Widikind Lenz and threatened legal action, but did agree to a warning label ... and then finally after years of tragedy, removed it from the market.”
  — Katie Hafner ([26:54])

• On the real-world cost of lack of rigor:

  “There is this one doctor who was a golfing buddy... And [he] allegedly writes this paper in a journal declaring the drug very safe. And it was actually written by the Merrell people. Hello?”
  — Katie Hafner ([35:43])

Important Segment Timestamps

• Kelsey's unease with thalidomide data (early suspicions): [03:09]
• Her early experience with drug dangers and the FDA: [07:07]–[09:56]
• FDA’s powerlessness before 1938, law changes: [08:23]
• Merrell’s push and Kelsey’s stalling tactics: [12:13]–[14:49]
• Discovery of UK warning signs, obfuscation by Merrell: [18:53]–[21:24]
• European tragedies, Lenz exposes thalidomide: [22:37]–[26:54]
• Merrell’s reckless U.S. drug distribution: [34:17]–[36:47]
• Kelsey’s recognition and subsequent FDA reforms: [37:24]–[38:53]
• Discussion of thalidomide’s later uses: [40:11]
• Misinterpretations of Kelsey’s legacy (RFK Jr. anecdote): [41:47]–[42:36]
• Kelsey’s later career and quiet heroism: [42:55]–[43:41]

Final Thoughts & Tone

The episode weaves a suspenseful, intimate story, blending admiration for Kelsey’s dogged, data-driven caution with frustration and horror at pharmaceutical and regulatory failures. There’s gentle humor (“Nothing says Christmas like a sleeping pill” — Tim), deep empathy for victims, and a clear-eyed analysis of system-level change. Both Tim Harford and Katie Hafner’s tone is inquisitive and respectful, celebrating persistence, scientific integrity, and a critical balance between safety and innovation.

For Further Listening

• Lost Women of Science podcast by Katie Hafner, for more unsung stories of groundbreaking women in science.

Summary prepared for those who may have missed the episode, as an in-depth, chronological guide to Frances Oldham Kelsey’s fight—a cautionary tale of science, skepticism, and stewardship.